Drugs from Eli Lilly and Boehringer Ingelheim grabbed the spotlight at the EASL congress on liver diseases, both showing promising results in metabolic dysfunction-associated steatohepatitis (MASH).
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
Bobby "Boris" Pickett was one-half of the minds behind "Monster Mash," but that's barely half his life story Every Halloween, Robert George Pickett rises from the grave. (Figuratively.) The song that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results